Solvonis Therapeutics investor webinar on SVN-001, addiction treatment and mental health development milestones

Solvonis Therapeutics plc presents an investor webinar focused on its SVN-001 programme for severe alcohol use disorder, alongside a broader pipeline addressing addiction and mental health. Chief Executive Officer Anthony Tennyson and Chief Scientific Officer Professor David Nutt present the company’s strategy, while in-house analyst Barry Gibb chairs the discussion. The session is intended to explain the clinical and commercial milestones supporting Solvonis’ ambition to become a sector leader. Turner Pope Investments is scheduled to host the webinar on 15 October 2026. The supplied page content is limited to a connection-security notice, so the summary relies on the accompanying metadata and cannot assess the scientific evidence, trial results, financial claims, or detailed presentation content.